A Quick Primer On Roche's Immuno-Oncology Assets
Roche's broad cancer immunotherapy pipeline features a dozen novel agents, including the first candidates from new therapeutic platforms for bispecific antibodies and personalized cancer vaccines.
Roche's broad cancer immunotherapy pipeline features a dozen novel agents, including the first candidates from new therapeutic platforms for bispecific antibodies and personalized cancer vaccines.